NCT00634413View on ClinicalTrials.gov

Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Theophylline - ADC4022

Inhaled theophylline (ADC4022) administered twice daily for 28 days

DRUG

Placebo

Inhaled matching placebo administered twice daily for 28 days

DRUG

Budesonide

Inhaled budesonide twice daily for 28 days

Trial Locations (8)

40-752

Silisian Medical University, Katowice-Ligota

31-066

Jagiellonian University of Medicine, Krakow

01-138

National Tuberculosis and Lung Diseases Research Institute, Warsaw

02-097

Warsaw University Medical School, Warsaw

90-153

Medical University in Lodz, Lodz

LE3 9QP

Glenfield Hospital, Leicester

E2 9JX

The London Chest Hospital, London

M23 9QZ

Medicines Evaluation Unit, Manchester

Sponsors
All Listed Sponsors
lead

Pulmagen Therapeutics

INDUSTRY